- Home
- KALV vs CAC Comparison
KALV vs CAC Comparison
Compare KALV & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- CAC
- Stock Information
- Founded
- KALV N/A
- CAC 1875
- Country
- KALV United States
- CAC United States
- Employees
- KALV N/A
- CAC N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- CAC Major Banks
- Sector
- KALV Health Care
- CAC Finance
- Exchange
- KALV Nasdaq
- CAC Nasdaq
- Market Cap
- KALV 796.4M
- CAC 688.3M
- IPO Year
- KALV N/A
- CAC 1997
- Fundamental
- Price
- KALV $13.50
- CAC $39.80
- Analyst Decision
- KALV Strong Buy
- CAC Buy
- Analyst Count
- KALV 8
- CAC 3
- Target Price
- KALV $26.43
- CAC $48.00
- AVG Volume (30 Days)
- KALV 1.0M
- CAC 55.1K
- Earning Date
- KALV 09-11-2025
- CAC 10-28-2025
- Dividend Yield
- KALV N/A
- CAC 4.17%
- EPS Growth
- KALV N/A
- CAC 4.80
- EPS
- KALV N/A
- CAC 3.11
- Revenue
- KALV $1,426,000.00
- CAC $197,501,000.00
- Revenue This Year
- KALV N/A
- CAC $42.11
- Revenue Next Year
- KALV $213.43
- CAC $5.51
- P/E Ratio
- KALV N/A
- CAC $12.93
- Revenue Growth
- KALV N/A
- CAC 21.74
- 52 Week Low
- KALV $7.30
- CAC $34.53
- 52 Week High
- KALV $17.28
- CAC $50.07
- Technical
- Relative Strength Index (RSI)
- KALV 44.26
- CAC 47.42
- Support Level
- KALV $13.26
- CAC $39.82
- Resistance Level
- KALV $17.28
- CAC $40.75
- Average True Range (ATR)
- KALV 1.03
- CAC 0.79
- MACD
- KALV -0.10
- CAC -0.06
- Stochastic Oscillator
- KALV 9.13
- CAC 12.06
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.